ADVATE Antihemophilic Factor (Recombinant) Kit
by Takeda Pharmaceuticals America, Inc. · 1 BLISTER PACK in 1 CARTON (0944-3046-10) / 1 CONTAINER in 1 BLISTER PACK (0944-3046-12) / 1 KIT in 1 CONTAINER (0944-3046-11) * 5 mL in 1 VIAL, GLASS (0944-2946-01) * 5 mL in 1 VIAL, GLASS (64764-515-50)
NDC 00944-3046-10
🏷️ FDA NDC (as labeled)
0944-3046-10
billing pads the labeler segment with a zero
Brand
On market
Non-controlled
🗂️ Data synced Sep 17, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
🆔 Identity & classification
FDA NDC (as labeled)
0944-3046-10
Product NDC
0944-3046
11-digit billing NDC
00944304610
NCPDP billing unit
EA — each (per item)
Application #
BLA125063
SPL Set ID
80fa03d2-cd4c-4155-9b57-1396c4fa42da
DEA schedule
Non-controlled
Marketing category
BLA
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
2007-07-03
Dosage form
KIT
GPI-14
85100010252180
GPI class
Advate
GCN Seq No
062863
GCN
98634
HICL code
041651
Ingredient (HICL)
Antihemophil.fviii,Full Length
HIC1 code
M
Therapeutic class — broad (HIC1)
Blood
HIC2 code
M0
Therapeutic class — intermediate (HIC2)
Blood And Blood Replacement Preparations
HIC3 code
M0E
Therapeutic class — specific (HIC3)
Antihemophilic Factors
AHFS code
20:28.16.00
AHFS class
Hemostatics
FDB label name
ADVATE 2,401-3,600 UNIT VIAL
FDB brand name
Advate
Legend status
F — Federal legend — prescription drug or device
Biologic (Purple Book)
351(a)
Why two NDCs?
The FDA registers this code as 0944-3046-10 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00944-3046-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
🏭 Manufacturer & labeler
LabelerTakeda Pharmaceuticals America, Inc.
FDA applicationBLA125063 (BLA)
Labeler code00944
First marketedJul 2007
Product typePlasma Derivative
Portfolio154 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
🩺 Clinical
Label name ADVATE 2,401-3,600 UNIT VIAL Ingredient Antihemophil.fviii,Full Length
Patient education
Supplement & herbal interactions
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
💬 Questions about Antihemophilic Factor (Recombinant)?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
A current SPL was checked, but it does not contain a structured or narrative inactive-ingredient list for this product. This does not mean the product has no inactive ingredients.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | $1.69 | — |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
| Medicare Part B allowsASP · J7192 | $1.580 / J7192 unit | — |
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
🧾 Billing & reimbursement
FDA NDC (as labeled)0944-3046-10
11-digit billing NDC00944-3046-10
Format4-4-2 as registered → padded to 5-4-2 for billing (zero added to the labeler segment)
HCPCS J-codeJ7192
DescriptorFactor viii (antihemophilic factor, recombinant) per i.u., not otherwise specified
Billing units / pkg1 units
Crosswalk sourceCMS ASP NDC-HCPCS Crosswalk
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Advate 00944-3052-02 | Takeda | 1 kit | — | — | FDA listed | — |
| Xyntha 58394-0013-01 | Wyeth | 1 kit | — | — | FDA listed | — |
| Kovaltry 00026-3828-50 | Bayer | 1 kit | — | — | FDA listed | — |
| Kovaltry 00026-3821-25 | Bayer | 1 kit | — | — | FDA listed | — |
| Advate 00944-3045-10 | Takeda | 1 kit | — | — | FDA listed | — |
| Advatethis 00944-3046-10 | Takeda | 1 kit | — | — | FDA listed | — |
| Advate 00944-3047-10 | Takeda | 1 kit | — | — | FDA listed | — |
| Xyntha 58394-0014-01 | Wyeth | 1 kit | — | — | FDA listed | — |
| Kovaltry 00026-3824-25 | Bayer | 1 kit | — | — | FDA listed | — |
| Kovaltry 00026-3826-50 | Bayer | 1 kit | — | — | FDA listed | — |
| Xyntha 58394-0023-03 | Wyeth | 1 kit | — | — | FDA listed | — |
| Xyntha 58394-0025-03 | Wyeth | 1 kit | — | — | FDA listed | — |
| Advate 00944-3053-02 | Takeda | 1 kit | — | — | FDA listed | — |
| Xyntha 58394-0022-03 | Wyeth | 1 kit | — | — | FDA listed | — |
| Advate 00944-3051-02 | Takeda | 1 kit | — | — | FDA listed | — |
| Xyntha 58394-0015-01 | Wyeth | 1 kit | — | — | FDA listed | — |
| Xyntha 58394-0016-03 | Wyeth | 1 kit | — | — | FDA listed | — |
| Xyntha 58394-0024-03 | Wyeth | 1 kit | — | — | FDA listed | — |
| Advate 00944-3054-02 | Takeda | 1 kit | — | — | FDA listed | — |
| Xyntha 58394-0012-01 | Wyeth | 1 kit | — | — | FDA listed | — |
| Kovaltry 00026-3822-25 | Bayer | 1 kit | — | — | FDA listed | — |
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
⏳ Availability & biosimilar status
🏛️
2003
First FDA approval
Jul 2003
📍
2026
Currently FDA-listed
23 years listed
🧬
·
Biosimilars
see Purple Book
🧬Biologic — competition comes from biosimilars
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
FDA Purple Book — biosimilars & interchangeables
ⓘ
Reference product
🔒 No FDA-licensed biosimilars or interchangeable biosimilars are listed yet for this biologic. It currently has no biosimilar competition in the FDA Purple Book.
Source: FDA Purple Book (purplebooksearch.fda.gov), matched on the reference product’s active ingredient.
Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.
🗺️ Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 00944-3046-10, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
448
Units reimbursed last 4 qtrs
7.4M
Gross reimbursed last 4 qtrs
$12.57M
Avg / prescription
$28,056.52
Avg / unit
$1.6887
Latest quarter Q4 2025
74Rx
Fee-for-service vs managed care ⓘ
Fee-for-service · 245 Rx Managed care · 203 Rx
State Medicaid map
Units reimbursed · per 100k residents
3478,829
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 00944-3046-10 You're viewing this | 1 BLISTER PACK in 1 CARTON (0944-3046-10) / 1 CONTAINER in 1 BLISTER PACK (0944-3046-12) / 1 KIT in 1 CONTAINER (0944-3046-11) * 5 mL in 1 VIAL, GLASS (0944-2946-01) * 5 mL in 1 VIAL, GLASS (64764-515-50) | 2007-07-03 | Active |
🧭 About this NDC listing & data coverage
Kit / multi-component package
Kit / multi-component package
This NDC identifies a kit — a package containing more than one component. Structured data (pricing, ingredients, equivalents) is often reported per component rather than for the kit NDC itself, which can make this page look thinner than the components' own pages.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | ✓ Available |
| Medicaid utilization (CMS SDUD) | ✓ Available |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 0944-3046-10, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 00944-3046-10, written without dashes as 00944304610. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 00944-3046-10, the first segment (00944) is the labeler code FDA assigned to Takeda Pharmaceuticals America, Inc.; the middle segment (3046) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (10) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Takeda Pharmaceuticals America, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Takeda Pharmaceuticals America, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Does this product have a billing J-code?
Yes — this NDC cross-references HCPCS code J7192 for medical-claim billing (typically used when a product is administered in a clinical setting rather than dispensed at a retail pharmacy). See the Billing section on this page.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
📄 Full FDA label FDA SPL
The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.